Sana Biotechnology, Inc.’s SANA share price has dipped by 5.61%, which has investors questioning if this is right time to buy ...

Zynlonta manufacturer ADC Therapeutics is continuing to prune its pipeline, calling time on its sole clinical-stage candidate ...

Cellectis S.A.'s financial picture remains strong, bolstered further by a partnership with AstraZeneca. Learn more about CLLS ...

Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and Ital ...

Q1 2025 Earnings Call Transcript May 14, 2025 ADC Therapeutics SA beats earnings expectations. Reported EPS is $-0.36, ...

The CD22-directed CAR-T, which was being tested in the FIRCE-1 study as a treatment for patients with relapsed/refractory large B-cell lymphoma (LBCL), was halted in January, with CARGO saying it ...

Welcome to the Legend Biotech’s First Quarter 2025 Earnings Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer ...

Patient dosing underway in CALiPSO-1 trial in the U.S.: In March 2025, the first patient was dosed in the Phase 1 CALiPSO-1 trial which is currently evaluating CNTY-101 as a potential treatment for ...